Kailera Therapeutics (KLRA) awards 38,300 stock options to director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable in full on April 16, 2027, as long as Milligan continues to serve the company through that date. Following this grant, he holds stock options for 38,300 underlying shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MILLIGAN JOHN F
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 38,300 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 38,300 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 38,300 options
Exercise price: $16.00 per share
Underlying shares: 38,300 shares
+3 more
6 metrics
Option grant size
38,300 options
Stock Option (right to buy) granted to director
Exercise price
$16.00 per share
Price to exercise options into common stock
Underlying shares
38,300 shares
Common stock underlying granted options
Vesting date
April 16, 2027
Options vest 100% on this date
Expiration date
April 16, 2036
Options lapse after this date
Options held after grant
38,300 options
Total options following transaction
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 16.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-04-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
What did director John F. Milligan receive in this KLRA Form 4 filing?
John F. Milligan received a grant of stock options for 38,300 shares of Kailera Therapeutics common stock. These options represent a compensation award rather than an open-market purchase or sale of existing shares.
What is the exercise price of John F. Milligan’s Kailera Therapeutics options?
The stock options granted to John F. Milligan have an exercise price of $16.00 per share. This is the price he must pay per share to convert the options into Kailera Therapeutics common stock once they are vested.
When do John F. Milligan’s KLRA stock options vest and become exercisable?
The options vest and become exercisable as to 100% of the underlying 38,300 shares on April 16, 2027. Vesting is conditioned on Milligan’s continued service with Kailera Therapeutics through that vesting date.
When do the Kailera Therapeutics stock options granted to Milligan expire?
The options granted to John F. Milligan expire on April 16, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase Kailera Therapeutics common stock at the $16.00 exercise price.